Display options
Cite
Barouky R, Badet M, Denis MS, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and disseminated aspergillosis. Eur J Intern Med. 2003;14(6):380-382doi: 10.1016/s0953-6205(03)90006-9.
Barouky, R., Badet, M., Denis, M. S., Soubirou, J. L., Philit, F., & Guerin, C. (2003). Inhaled corticosteroids in chronic obstructive pulmonary disease and disseminated aspergillosis. European journal of internal medicine, 14(6), 380-382. https://doi.org/10.1016/s0953-6205(03)90006-9
Barouky, Rime, et al. "Inhaled corticosteroids in chronic obstructive pulmonary disease and disseminated aspergillosis." European journal of internal medicine vol. 14,6 (2003): 380-382. doi: https://doi.org/10.1016/s0953-6205(03)90006-9
Barouky R, Badet M, Denis MS, Soubirou JL, Philit F, Guerin C. Inhaled corticosteroids in chronic obstructive pulmonary disease and disseminated aspergillosis. Eur J Intern Med. 2003 Oct;14(6):380-382. doi: 10.1016/s0953-6205(03)90006-9. PMID: 14769498.
Copy Download .nbib Format: NLM
Share it on

Eur J Intern Med. 2003 Oct;14(6):380-382. doi: 10.1016/s0953-6205(03)90006-9.

Inhaled corticosteroids in chronic obstructive pulmonary disease and disseminated aspergillosis.

European journal of internal medicine

Rime Barouky, Michel Badet, Marc Saint Denis, Jean Luc Soubirou, François Philit, Claude Guerin

Affiliations

  1. Service de Réanimation Médicale et d'Assistance Respiratoire, Hôpital de la Croix-Rousse, 93 Grande Rue de la Croix-Rousse, 69004 Lyon, France.

PMID: 14769498 DOI: 10.1016/s0953-6205(03)90006-9

Abstract

Inhaled corticosteroids are widely used in patients with chronic obstructive pulmonary disease (COPD), although their efficacy is still being debated. Due to local and systemic effects, such therapy can have an immunosuppressive action and opportunistic infections can occur. In the present case, a 74-year-old man treated with inhaled corticosteroids for 5 years developed disseminated aspergillosis. No other immunosuppressive factor was found. To our knowledge, only a few cases of lung aspergillosis in such patients have been described in the literature. However, the risk-to-benefit ratio of this treatment must be reassessed.

Publication Types